Skip to main content
News

TNF Inhibitors May Increase Inflammatory Central Nervous System Events Risk

Tumor necrosis factor (TNF) inhibitors have significantly changed the therapeutic landscape for many autoimmune diseases, such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. While these therapies are commonly used with success among many patients, a recent study suggested a potential association between TNF exposure and increased risk for inflammatory central nervous system (CNS) events. Specifically, the study showed patients treated with TNF inhibitors had a 3-fold increased risk, and those with rheumatoid arthritis had nearly a 5-fold increased risk.

Using medical records from 3 Mayo Clinic locations, the researchers analyzed TNF exposure, type of TNF therapy, cumulative duration of exposure, and time of exposure among 106 patients with autoimmune diseases with an FDA-approved indication for TNF inhibitors between January 1, 2003, and February 20, 2019 (ie, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis). They identified patients diagnosed with demyelinating (multiple sclerosis and other diseases, such as optic neuritis) or nondemyelinating (meningitis, meningoencephalitis, encephalitis, neurosarcoidosis, and CNS vasculitis) CNS events and matched them with 106 controls by year of birth, type of autoimmune disease, and sex.
_____________________________________________________
Related content

TKIs Associated With Respiratory Tract Infections
Combination MTX With TNF Lowers Discontinuation Rates
Do Biologic Therapies Increase the Risk for Melanoma?
Oral Brown Spots Not Predictive of Retinal Toxicity in Patients Taking Antimalarial Drugs for Lupus
_____________________________________________________

The researchers evaluated associations between TNF inhibitor use and CNS events using conditional logistic regression and adjusted for disease duration to determine odds ratios (OR). In secondary analyses, they stratified outcomes by inflammatory demyelinating and nondemyelinating CNS events and autoimmune disease (rheumatoid arthritis and non-rheumatoid arthritis).

Overall, 64 patients (60%) and 42 controls (40%) were treated with a TNF inhibitor. Exposure to TNF inhibitors was associated with an increased risk for any inflammatory CNS event (adjusted OR 3.01; 95% CI, 1.55-5.82), the researchers said. They also observed similar results when the outcome was stratified by demyelinating and nondemyelinating CNS events.

In secondary analyses, the researchers found this association was predominately observed in patients with rheumatoid arthritis (adjusted OR 4.82; 95% CI, 1.62-14.36).

“The association observed between exposure to TNF inhibitor and increased risk of inflammatory demyelinating and nondemyelinating central nervous system events warrants future research to ascertain whether the association may indicate de novo inflammation or exacerbation of already aberrant inflammatory pathways,” the researchers concluded.

Reference

Kunchok A, Aksamit AJ, Davis JM, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events [published online May 18, 2020]. JAMA Neurol. doi:10.1001/jamaneurol.2020.1162